Anthony Chan
Dr. Anthony Chan is a pediatric hematologist/oncologist and is one of the leading experts in the field of pediatric thrombosis and stroke. More specifically, Dr. Chan is a Professor (Pediatrics) at McMaster and is currently the Division Chief of Pediatric Hematology/Oncology and the Director (Pediatrics) of the Hemophilia Treatment Centre at McMaster Children's Hospital. He holds the inaugural McMaster Children’s Hospital/Hamilton Health Sciences Foundation Chair in Pediatric Thrombosis and Hemostasis. He is also a clinician scientist where his research is focused on the development of a novel anticoagulant, control of thrombin on the surface of biomaterials, understanding the development of the haemostatic system with specific focus on glycosylation of different coagulation inhibitors and coagulation proteins, and the understanding of coagulation in pediatric patients undergoing cardiopulmonary bypass. He is involved in designing clinical trials in pediatric thrombosis and pediatric stroke as well as providing around-the-clock free consultation worldwide through the 1-800-NOCLOTS service.
Email: akchan@mcmaster.ca
Research Interests of the Lab:
Dr. Chan’s research at the Thrombosis and Atherosclerosis Research Institute is focused on, but is not limited to, two main areas: 1) the study of the hemostatic system in the young, and 2) the characterization of a novel covalent antithrombin-heparin complex (ATH). These areas are briefly described below:
1) Research is done looking at age-related coagulation, specifically hemostatic mechanisms related to pediatric diseases. One area of interest is the variation in glycosylation of coagulation factors during development. Glycan heterogeneity has been found for several factors within the hemostatic system, and it is of interest to look at developmental glycosylation differences as well. The results may provide insight to better treat pediatric patients with diseases related to coagulation.
2) Dr. Chan has developed ATH. The potential of ATH as a potent pulmonary and systemic anticoagulant for the treatment of thrombosis is being studied at length. Furthermore, potential applications of this drug include surface coating of biomaterials (making them less thrombogenic), and as an agent for the treatment of respiratory distress syndrome.
